Hepatitis B virus infection
MF Yuen, DS Chen, GM Dusheiko… - Nature reviews Disease …, 2018 - nature.com
Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic
infection in humans through immune anergy. Currently, 3.5% of the global population is …
infection in humans through immune anergy. Currently, 3.5% of the global population is …
[HTML][HTML] KASL clinical practice guidelines for management of chronic hepatitis B
Korean Association for the Study of the … - Clinical and …, 2019 - ncbi.nlm.nih.gov
Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
Chronic infection with hepatitis B virus (HBV) leads to an increased risk of death from
cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment …
cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment …
Current trends and limitations in dengue antiviral research
Dengue is the most prevalent arthropod-borne viral disease worldwide and affects
approximately 2.5 billion people living in over 100 countries. Increasing geographic …
approximately 2.5 billion people living in over 100 countries. Increasing geographic …
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
L Eyer, R Nencka, E de Clercq… - Antiviral Chemistry …, 2018 - journals.sagepub.com
Nucleoside analogs represent the largest class of small molecule-based antivirals, which
currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis …
currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis …
APASL guidance on stop** nucleos (t) ide analogues in chronic hepatitis B patients
Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy
Conclusions HBV RNA showed distinct and corresponding profiles in patients with HBV in
different disease phases. HBV RNA and HBcrAg could be used to monitor residual …
different disease phases. HBV RNA and HBcrAg could be used to monitor residual …
HBV-integration studies in the clinic: role in the natural history of infection
T Pollicino, G Caminiti - Viruses, 2021 - mdpi.com
Hepatitis B virus (HBV) infection is a major global health problem causing acute and chronic
liver disease that can lead to liver cirrhosis and hepatocellular carcinoma (HCC). HBV …
liver disease that can lead to liver cirrhosis and hepatocellular carcinoma (HCC). HBV …
Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B
Background Long-term incidences and baseline determinants of functional cure (hepatitis B
surface antigen [HBsAg] seroclearance) during entecavir (ETV) or tenofovir disoproxil …
surface antigen [HBsAg] seroclearance) during entecavir (ETV) or tenofovir disoproxil …
[HTML][HTML] Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection
Background & Aims The outcome of HBV infection, including the dynamics of HBsAg and
HBV virological reactivation, among patients coinfected with HCV receiving direct-acting …
HBV virological reactivation, among patients coinfected with HCV receiving direct-acting …